Oncological management of the operated patient: adjuvant chemotherapy, surveillance, treatment of recurrences
Fiche publication
Date publication
septembre 2008
Auteurs
Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie
Tous les auteurs :
Westeel V, Moro-Sibilot D
Lien Pubmed
Résumé
Despite recent progress obtained from perioperative chemotherapy and particularly, that demonstrated by the clinical trials on adjuvant chemotherapy, recurrences remain frequent after surgery for non-small cell lung cancer. Research on adjuvant treatments is ongoing, focused on targeted therapies or personalised therapeutic strategies. Other questions remain unanswered and are still investigated in clinical trials by the French Cancer Institute, such as thoracic radiotherapy for N2 disease, surveillance and treatment of recurrences. Although post-surgical surveillance, with or without chemotherapy, may theoretically increase survival by an earlier detection of recurrences, there are no evidence-based data. With the wide use of adjuvant chemotherapy, the profile of recurrences is likely to change and the best chemotherapy for metastatic recurrences remains to be defined.
Référence
Oncologie. 2008 Sep;10(9):525-8